Fesoterodine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fesoterodine
Fesoterodine.svg
Space-filling model of the fesoterodine molecule
Clinical data
Trade names Toviaz
AHFS/Drugs.com Monograph
MedlinePlus a609021
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 52% (active metabolite)
Protein binding 50% (active metabolite)
Metabolism Hepatic (CYP2D6- and 3A4-mediated)
Biological half-life 7–8 hours (active metabolite)
Excretion Renal (70%) and fecal (7%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.167.339
Chemical and physical data
Formula C26H37NO3
Molar mass 411.278 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.

Efficacy[edit]

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]

References[edit]